Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 1, 2010, Pages 95-100

  Innala, Eva ^a   Bäckström, Torbjörn ^a   Bixo, Marie ^a   Andersson, Christer ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Add back; GnRH agonist therapy; Menstrual; Porphyria

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; GONADORELIN; PROGESTERONE;

ACUTE INTERMITTENT PORPHYRIA; ADULT; ARTICLE; DRUG POTENTIATION; FEMALE; HUMAN; LUTEAL PHASE; MENSTRUATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ESTRADIOL; ESTROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEAL PHASE; MENSTRUATION; PORPHYRIA, ACUTE INTERMITTENT; PROGESTERONE; PROGESTINS; YOUNG ADULT;

EID: 74049096557     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016340903390729     Document Type: Article

References (28)

1. Anderson KE, Sassa S, Bishop D.F., Desnick RJ Disorders of Heme Biosynthesis: X-Linked Sideroblastic Anemia and the Porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001. pp. 2991-3062.
2. Von Und Zu Fraunberg M, Timonen K, Mustajoki P, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in Finnish variegate porphyria patients. Eur J Hum Genet. 2002; 10:649-57.
3. Thunell S, Floderus Y, Henrichson A., Harper P. Porphyria in Sweden. Physiol Res. 2006; 55:S109-18.
4. Lee JS, Anvret M. Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermittent porphyria. Proc Natl Acad Sci USA. 1991; 88:10912-5.
5. Andersson C, Thunell S, Floderus Y., Forsell C, Lundin G, Anvret M., et al Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods. J Intern Med. 1995; 237:301-8.
6. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore). 1992; 71:1-13.
7. Andersson C, Floderus Y, Wikberg A., Lithner F. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study. Scand J Clin Lab Invest. 2000; 60:643-8.
8. Bonnin A, Picornell A, Orfila J., Castro JA, Ramon MM Clinic and genetic evaluation of variegate porphyria (VP) in a large family from the Balearic Islands. [PDF] 2009 [updated Feb 20; cited 2009 0512]; 2009/02/21: Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=19229653.
9. McColl KE, Wallace AM, Moore M.R., Thompson GG, Goldberg A. Alterations in haem biosynthesis during the human menstrual cycle: studies in normal subjects and patients with latent and active acute intermittent porphyria. Clin Sci (Lond). 1982; 62:183-91.
10. Anderson KE, Spitz IM, Sassa S, Bardin C.W., Kappas A. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med. 1984; 311:643-5.
11. Anderson KE. LHRHanalogues for hormonalmanipulation in acute intermittent porphyria. Semin Hematol. 1989; 26:10-5.
12. Elder GH, Hift RJ, Meissner PN The acute porphyrias. Lancet. 1997; 349:1613-7.
13. Andersson C, Innala E, Backstrom T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med. 2003; 254:176-83.
14. Hift RJ, Meissner PN An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore). 2005; 84:48-60.
15. Anderson KE, Spitz IM, Bardin C.W., Kappas A. A gonado-tropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med. 1990; 150:1469-74.
16. Herrick AL, McColl KE, Wallace A.M., Moore MR, Goldberg A. LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria. Q J Med. 1990; 75:355-63.
17. Kappas A. Studies in porphyria. I. A defect in the reductive transformation of natural steroid hormones in the hereditary disease, acute intermittent porphyria. J Exp Med. 1972; 136: 1043-53.
18. Anderson KE, Bradlow HL, Sassa S, Kappas A. Studies in porphyria. VIII. Relationship of the 5 alpha-reductive metabolism of steroid hormones to clinical expression of the genetic defect in acute intermittent porphyria. Am J Med. 1979; 66: 644-50.
19. De Block C.E., Leeuw IH, Gaal LF Premenstrual attacks of acute intermittent porphyria: hormonal and metabolic aspects - a case report. Eur J Endocrinol. 1999; 141:50-4.
20. Studd J, Leather AT The need for add-back with gonadotrophin-releasing hormone agonist therapy. Br J Obstet Gynaecol. 1996; 103:1-4.
21. Utian WH, Archer DF, Bachmann G.A., Gallagher C., Grodstein F, Heiman JR, et al Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008; 15:584-602.
22. Odmark IS, Bixo M, Englund D., Risberg B, Jonsson B, Olsson SE Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy. Menopause. 2005; 12:699-707.
23. Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand. 1988; 67:159-66.
24. Sundstrom I, Nyberg S, Bixo M., Hammarback S, Backstrom T. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand. 1999; 78:891-9.
25. Hirvonen E, Salmi T, Puolakka J., Heikkinen J, Granfors E, Hulkko S., et al Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas. 1995; 21:39-44.
26. Boerrigter PJ, van de Weijer PH, Baak JP, Fox H, Haspels AA, Kenemans P. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Maturitas. 1996; 24:63-71.
27. Soonawalla ZF, Orug T, Badminton M.N., Elder GH, Rhodes JM, Bramhall SR, et al Liver transplantation as a cure for acute intermittent porphyria. Lancet. 2004; 363:705-6.
28. Lithner F. Could attacks of abdominal pain in cases of acute intermittent porphyria be due to intestinal angina? J Intern Med. 2000; 247:407-9.